Patients must understand warning signs and know when to seek care
While the WeightWatchers Ozempic alternative offers a lower-cost option for those looking for GLP-1 treatments, it's not without controversy
Abdel-Razek, E
A British Journal of Pharmacology review published January 2026 examining GLP-1 receptor agonists and muscle strength changes in older adults concluded that "future randomized, double-blinded trials with adequate sample sizes and longer follow-ups are warranted, particularly in older populations who are at an increased risk of sarcopenia." Where the Risk Is Highest The risk is highest for older adults who: Are already at or near the threshold for sarcopenia (low baseline muscle mass and strength) before starting a GLP-1 drug Lose weight rapidly, at more than 1.5 kg per week, which amplifies lean mass loss relative to fat Do not engage in resistance exercise during treatment, which is the primary protective intervention against muscle loss on GLP-1 drugs Have low baseline protein intake or difficulty increasing protein consumption due to reduced appetite on the drug Have multiple chronic conditions requiring several concurrent medications, increasing the risk of drug interactions and compounding dehydration Are over 75, for whom functional decline from muscle loss has more immediate consequences for independence Geographically, older adult populations in Sun Belt metro areas (Phoenix, Miami, Tampa, Las Vegas, Jacksonville, and others) are among the highest-density Medicare populations in the country, and the regions where GLP-1 prescribing is growing fastest in newly eligible Medicare enrollees
Further development results in a completely intradermal lesion called the dermal nevus
Group Fitness and Community Support Many members find motivation through group fitness classes and supportive fitness communities
